Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10

Trial Profile

Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication AMLSG 16-10

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Midostaurin (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AMLSG16-10
  • Most Recent Events

    • 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2017 Results studying the clonal evolution in paired samples obtained at diagnosis (D) and relapse (R) by whole exome sequencing (WES) in FLT3-ITDpos AML pts enrolled by the AMLSG and treated in the RATIFY (NCT00651261) or AMLSG 16-10 (NCT01477606) trial presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results of the Plasma Inhibitor Activity (PIA) Analysis (n=118) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top